Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy

David L. Hemsell, Steven G. Bernstein, Roger E. Bawdon, Patricia G. Hemsell, Molly C. Heard, Brenda J. Nobles

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Twenty-one women who underwent radical abdominal hysterectomy and pelvic lymphadenectomy were enrolled in a prospective, comparative, randomized, placebo-controlled clinical trial of antimicrobial prophylaxis. Preoperative endocervical flora was identified and was similar in pre- and postmenopausal private and clinic service women; 46% of the 119 preoperative isolates produced β-lactamase enzyme. Women were given three doses of either placebo or cefoperazone plus sulbactam, an irreversible β-lactamase enzyme inhibitor. Three women (27%) given placebo developed abdominal incision infections; one woman given placebo also developed a pelvic infection. None given antibiotic developed operative site infection, but one woman developed a drain site infection. A major operative site infection rate of 27% observed with placebo is high enough to warrant prophylaxis. Although antimicrobial prophylaxis at radical hysterectomy and pelvic lymphadenectomy eradicted operative site infection in our patient populations, a literature review indicates that individual determination of a requirement for prophylaxis is necessary.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalGynecologic Oncology
Volume35
Issue number1
DOIs
StatePublished - 1989

Fingerprint

Lymph Node Excision
Hysterectomy
Placebos
Infection
Pelvic Infection
Cefoperazone
Sulbactam
Enzyme Inhibitors
Randomized Controlled Trials
Anti-Bacterial Agents
Enzymes
Population

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy. / Hemsell, David L.; Bernstein, Steven G.; Bawdon, Roger E.; Hemsell, Patricia G.; Heard, Molly C.; Nobles, Brenda J.

In: Gynecologic Oncology, Vol. 35, No. 1, 1989, p. 55-60.

Research output: Contribution to journalArticle

Hemsell, David L. ; Bernstein, Steven G. ; Bawdon, Roger E. ; Hemsell, Patricia G. ; Heard, Molly C. ; Nobles, Brenda J. / Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy. In: Gynecologic Oncology. 1989 ; Vol. 35, No. 1. pp. 55-60.
@article{dae41de13e3f479c89a0888f7c9b0669,
title = "Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy",
abstract = "Twenty-one women who underwent radical abdominal hysterectomy and pelvic lymphadenectomy were enrolled in a prospective, comparative, randomized, placebo-controlled clinical trial of antimicrobial prophylaxis. Preoperative endocervical flora was identified and was similar in pre- and postmenopausal private and clinic service women; 46{\%} of the 119 preoperative isolates produced β-lactamase enzyme. Women were given three doses of either placebo or cefoperazone plus sulbactam, an irreversible β-lactamase enzyme inhibitor. Three women (27{\%}) given placebo developed abdominal incision infections; one woman given placebo also developed a pelvic infection. None given antibiotic developed operative site infection, but one woman developed a drain site infection. A major operative site infection rate of 27{\%} observed with placebo is high enough to warrant prophylaxis. Although antimicrobial prophylaxis at radical hysterectomy and pelvic lymphadenectomy eradicted operative site infection in our patient populations, a literature review indicates that individual determination of a requirement for prophylaxis is necessary.",
author = "Hemsell, {David L.} and Bernstein, {Steven G.} and Bawdon, {Roger E.} and Hemsell, {Patricia G.} and Heard, {Molly C.} and Nobles, {Brenda J.}",
year = "1989",
doi = "10.1016/0090-8258(89)90011-5",
language = "English (US)",
volume = "35",
pages = "55--60",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy

AU - Hemsell, David L.

AU - Bernstein, Steven G.

AU - Bawdon, Roger E.

AU - Hemsell, Patricia G.

AU - Heard, Molly C.

AU - Nobles, Brenda J.

PY - 1989

Y1 - 1989

N2 - Twenty-one women who underwent radical abdominal hysterectomy and pelvic lymphadenectomy were enrolled in a prospective, comparative, randomized, placebo-controlled clinical trial of antimicrobial prophylaxis. Preoperative endocervical flora was identified and was similar in pre- and postmenopausal private and clinic service women; 46% of the 119 preoperative isolates produced β-lactamase enzyme. Women were given three doses of either placebo or cefoperazone plus sulbactam, an irreversible β-lactamase enzyme inhibitor. Three women (27%) given placebo developed abdominal incision infections; one woman given placebo also developed a pelvic infection. None given antibiotic developed operative site infection, but one woman developed a drain site infection. A major operative site infection rate of 27% observed with placebo is high enough to warrant prophylaxis. Although antimicrobial prophylaxis at radical hysterectomy and pelvic lymphadenectomy eradicted operative site infection in our patient populations, a literature review indicates that individual determination of a requirement for prophylaxis is necessary.

AB - Twenty-one women who underwent radical abdominal hysterectomy and pelvic lymphadenectomy were enrolled in a prospective, comparative, randomized, placebo-controlled clinical trial of antimicrobial prophylaxis. Preoperative endocervical flora was identified and was similar in pre- and postmenopausal private and clinic service women; 46% of the 119 preoperative isolates produced β-lactamase enzyme. Women were given three doses of either placebo or cefoperazone plus sulbactam, an irreversible β-lactamase enzyme inhibitor. Three women (27%) given placebo developed abdominal incision infections; one woman given placebo also developed a pelvic infection. None given antibiotic developed operative site infection, but one woman developed a drain site infection. A major operative site infection rate of 27% observed with placebo is high enough to warrant prophylaxis. Although antimicrobial prophylaxis at radical hysterectomy and pelvic lymphadenectomy eradicted operative site infection in our patient populations, a literature review indicates that individual determination of a requirement for prophylaxis is necessary.

UR - http://www.scopus.com/inward/record.url?scp=0024439306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024439306&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(89)90011-5

DO - 10.1016/0090-8258(89)90011-5

M3 - Article

C2 - 2792903

AN - SCOPUS:0024439306

VL - 35

SP - 55

EP - 60

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -